Furthermore, in patients with CKD, with and without diabetes, the sodium glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin is now approved for the treatment of CKD, following the positive results of the DAPA-CKD trial [7]. The gene discussed is SLC5A2; the disease is diabetes mellitus.